print
Trabectedin for second-line recurrent platinum-sensitive ovarian cancer
- Source agency:
- LBI -HTA
- Date of Submission:
- 16/03/2010
- Date of Printing:
- 05/02/2012
- Technology name:
- Trabectedin, Yondelis ®
- Technology - type(s):
- Drug
- Patient indications:
- Trabectedin is indicated for the treatment of patients (pts) with advanced, recurrent/relapsed platinum-sensitive ovarian cancer in combination with pegylated liposomal doxorubicin (PLD).